MétaCan
Menu
Back to cohort
Record W2944179533 · doi:10.1158/1078-0432.ccr-19-0191

<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma

2019· article· en· W2944179533 on OpenAlexafffund
Martin Jones, Laura Williamson, James T. Topham, Michael K.C. Lee, Angela Goytain, Julie Ho, Robert E. Denroche, Gun-Ho Jang, Erin Pleasance, Joanna M. Karasinska, John Paul McGhie, Sharlene Gill, Howard J. Lim, Malcolm J. Moore, Hui‐Li Wong, Tony Ng, Stephen Yip, Wei Zhang, Sara Sadeghi, Carolyn Reisle, Andrew J. Mungall, Karen Mungall, Richard A. Moore, Yussanne Ma, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, David F. Schaeffer, Steven J.M. Jones, Daniel J. Renouf

Bibliographic record

VenueClinical Cancer Research · 2019
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsUniversity of British ColumbiaLunenfeld-Tanenbaum Research InstituteVancouver General HospitalOntario Institute for Cancer ResearchSimon Fraser UniversityPrincess Margaret Cancer CentreBC Cancer AgencyPancreas Centre (Canada)Canada's Michael Smith Genome Sciences Centre
FundersBC Cancer FoundationGenome British ColumbiaPfizerEli Lilly and Company
KeywordsKRASAfatinibAdenocarcinomaPancreatic cancerCancer researchMedicineFusion geneOncologyERBB3Neuregulin 1CancerBiologyGeneInternal medicineErlotinibGeneticsEpidermal growth factor receptorReceptorColorectal cancer

Abstract

fetched live from OpenAlex

Abstract Purpose: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of NRG1 fusion–positive pancreatic ductal adenocarcinoma is not fully understood. Experimental Design: Forty-seven patients with pancreatic ductal adenocarcinoma received comprehensive whole-genome and transcriptome sequencing and analysis. Two patients with gene fusions involving NRG1 received afatinib treatment, with response measured by pretreatment and posttreatment PET/CT imaging. Results: Three of 47 (6%) patients with advanced pancreatic ductal adenocarcinoma were identified as KRAS wild type by whole-genome sequencing. All KRAS wild-type tumors were positive for gene fusions involving the ERBB3 ligand NRG1. Two of 3 patients with NRG1 fusion–positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy. Conclusions: This work adds to a growing body of evidence that NRG1 gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with KRAS wild-type tumors harboring NRG1 gene fusions may benefit from treatment with afatinib. See related commentary by Aguirre, p. 4589

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.006
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0010.003
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0060.009
Insufficient payload (model declined to judge)0.0020.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.220
GPT teacher head0.516
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations159
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicPancreatic and Hepatic Oncology ResearchFrench-language works237,207